Urinary tract infections (UTIs) can be treated using antibiotic pills known as methenamine hippurate. These pills contain methenamine hippurate, a urinary antiseptic that inhibits the development of bacteria in the genitourinary system.
UTIs are commonly treated temporarily with oral methenamine hippurate tablets, which are taken orally. The pills contain formaldehyde, a bactericidal agent that is released when they disintegrate in the urine and kill or limit the growth of germs in the urinary system.
Many patients who suffer from recurring UTIs take methenamine hippurate tablets on a preventative basis. Patients with compromised immune systems, such as those with spinal cord injuries or those who use urine catheters, may be prescribed these tablets to help keep infections at bay.
Zion Market Research estimates the global market for methenamine hippurate tablets to be valued $8.91 billion in 2022 and $14.74 billion by 2030, expanding at a CAGR (compound annual growth rate) of around 6.51% between 2023 and 2030.
The manufacturing and distribution of methenamine hippurate tablets, antibiotics used to treat bacterial UTIs, is referred to as the methenamine hippurate tablets industry. The urethra, kidneys, ureters, and bladder are all susceptible to the infection as well as any other portion of the urinary system. Methenamine salts is another name for these antacids used to treat UTIs. The sorority is in charge of developing and marketing methenamine hippurate tablets as well as doing related scientific research. One of the primary current contributors to medical research and development comes from the pharmaceutical industry. Several ground-breaking research efforts concerning the further application and development of the drug have been done over the past three years, and this bodes well for the industry’s future growth throughout the predicted period.
The rising number of women in the world means more demand for methenamine hippurate tablets. Women are more likely to get UTIs than men because of physiological differences in their urinary systems. Demand in this sector is expected to rise as a result of the rising proportion of women in the population. Medical problems such as diabetes, kidney stones, and urinary tract abnormalities, as well as some forms of birth control drugs like diaphragms, can also contribute to the development of the infection. These elements also contribute to the expansion of the fraternity’s ideal clientele.
During the foreseen time period, the increasing global healthcare expenditure is also significant. The aging population, the rise in the prevalence of chronic diseases, and the rising demand for healthcare services all contribute to rising healthcare costs. Constant efforts to improve technology also contribute to the expansion of the market. Innovations in drug delivery systems and other technologies are essential to the progress of medicine.
The methenamine hippurate tablets market may have stable expansion, but it is also projected to face growth limits, particularly in light of increased worries over the drugs’ potential side effects. Symptoms include nausea, vomiting, diarrhea, and itching skin to name a few. The pharmaceutical sector may never attain its full potential until its players can offer drugs with no negative medical effects. Further impediments to market expansion include patent expiration, the availability of generic alternatives, and low levels of patient knowledge, especially in developing economies.
The global methenamine hippurate tablets market is segmented based on application, type, distribution channel, end-users, and region.
Based on application, the global market segments are healthcare-associated UTIs and uncomplicated UTIs. In 2022, the industry registered the highest growth in the uncomplicated UTIs segment. This is mainly because this type of infection is generally caused by bacteria which can be treated with methenamine hippurate tablets since the bacteria is susceptible to the medicines and can be treated with it alone. However, healthcare-associated UTIs are generally caused by more serious conditions and may be the result of antibiotic-resistant bacteria. In such cases, medical professionals may prescribe the tablet in combination with other antibiotics. In the United States, UTIs are estimated to be responsible for over 8.1 million medical visits every year.
Based on type, the methenamine hippurate tablets industry divisions are 6 tablets/ bottle and 20 tablets/bottle. In 2022, the industry witnessed the highest growth in the 20 tablets/bottle segment since this type of medication is more common in people who may be in need of long-term UTI prophylaxis. Since the number of tablets in this segment is more, the entire treatment plan may be more cost-effective as compared to bottles with a lesser number of tablets. The 6 tablets/bottle segment is more commonly used for patients who require shorter UTI prophylaxis or people who prefer smaller sizes for better portability. The average cost of these tablets with all dosages and packaging sizes combined is around $32 USD per 100 tablets.
Based on distribution channel, the industry divisions are online pharmacy, hospital pharmacy, and retail pharmacy.
North America is expected to lead the global methenamine hippurate tablets market owing to the high awareness rate amongst the population about the benefits of using the medication. Furthermore, the presence of key pharmaceutical industry players who are regularly investing in the development of new methenamine hippurate-based products is expected to work in the favor of the regional industry. In Europe, the growth may be driven by the rising demand for preventive care as well as the growing demand for over-the-counter medications. Africa may not register high CAGR mainly due to a lack of awareness and the absence of adequate medical architecture in the region along with a lack of financial assistance leading to many people not having proper access to medical treatments.
The global methenamine hippurate tablets market is home to players like:
- Mylan N.V.
- Merck & Co. Inc.
- Cadila Healthcare Ltd.
- Pfizer Inc.
- Dr. Reddy’s Laboratories Ltd.
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- West-Ward Pharmaceuticals Corp.
- Abbott Laboratories
- Glenmark Pharmaceuticals Ltd.
- Bausch Health Companies Inc.
- Procter & Gamble Co.
- Jubilant Life Sciences Ltd.
- Lupin Pharmaceuticals Inc.
- Cipla Ltd.
- Amneal Pharmaceuticals LLC.
- Allergan plc.
- Novartis AG.
- Sanofi S.A.
The global methenamine hippurate tablets market is segmented as follows:
- Healthcare-associated UTIs
- Uncomplicated UTIs
- 6 Tablets/ Bottle
- 20 Tablets/Bottle
By Distribution Channel
- Online Pharmacy
- Hospital Pharmacy
- Retail Pharmacy
- Homecare, Hospitals
- Specialty Clinics
- North America
- The U.S.
- The UK
- Rest of Europe
- Asia Pacific
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- South Africa
- Rest of Middle East & Africa